Xconomy’s Digital Events →
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA... Read more »
Sponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.